Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel drug composition for curing hepatitis c virus

A composition and drug technology, applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., can solve the problem of lower infection efficiency of hepatitis C virus

Inactive Publication Date: 2013-06-05
WATERSTONE PHARMA WUHAN
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

"If the NPC1L1 protein can be prevented from functioning, the infection efficiency of hepatitis C virus can be significantly reduced, and it is expected to develop new methods for the prevention and treatment of hepatitis C in the future.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel drug composition for curing hepatitis c virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] In the present invention, when using ezetimibe and one or more anti-HCV drug compositions to treat viral hepatitis, ezetimibe and another anti-HCV drug can be administered together in one unit dose For example, the two or three are mixed to make unit dose tablet form, capsule form, or each exists in separate preparations, such as simply making etimibe tablet, bocepivir tablet Or ribavirin injection, the two are administered sequentially, and the administration is performed sequentially in this way, and the delayed administration of the second active ingredient should not reduce the synergistic effect between the combination of active ingredients. It should also be understood that ezetimibe, boceprevir or pharmaceutically acceptable derivatives thereof may be administered alone or in any combination, preferably simultaneously or in separate forms, regardless of simultaneous or sequential administration Administration is sequential, most preferably simultaneous.

[0031]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel antiviral drug composition and a method for curing hepatitis c virus (HCV) infection by using the novel type antiviral drug composition. The novel antiviral drug composition comprises 1 - (4-fluorine phenyl) - (3R)- [3 - (4 - fluorine phenyl) - (3S) - hydroxypropyl] - (4S) - (4 - hydroxypropyl) - 2-acrylic amide (ezetimibe, structural formula presented as graph 1) or acceptable derivatives in pharmaceutic preparation thereof, and an HCV resisting drug which is a drug composition selected from one kind or multiple kinds of boceprecir (BOC), telaprevir (TVR), pegylated interferon alpha (PEG - IFN alpha), interferon (IFNO) and ribavirin.

Description

Technical field: [0001] The present invention relates to a novel antiviral pharmaceutical composition, which comprises 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]- (4S)-(4-hydroxyphenyl)-2-propanolactam (ezetimibe, Ezetimibe, structural formula see figure 1 ) or its pharmaceutically acceptable derivatives, and anti-HCV (hepatitis C virus) drugs are selected from Boceprevir (BOC), Telaprevir (TVR), long-acting interferon (PEG-IFNα ), interferon (IFNα), ribavirin (Ribavirin) one or more of the pharmaceutical composition and the method for treating HCV infection, belong to the field of pharmaceutical preparations. Background technique: [0002] Hepatitis C virus, referred to as hepatitis C, hepatitis C, is a kind of viral hepatitis caused by hepatitis C virus (Hepatitis C virus, HCV) infection, mainly through blood transfusion, acupuncture, drug abuse, etc., according to the World Health Organization Organization statistics show that the global HCV infecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K45/00A61K31/397A61K31/7056A61K38/21A61K38/06A61K31/497A61P1/16A61P31/14
Inventor 刘大鹏张发明
Owner WATERSTONE PHARMA WUHAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com